News center
When the hand of time quietly slides to the end of the year of Dragon, we wave goodbye to the year of 2024. In this year, despite the complex and changing environment, SDMer always adhere to the spirit of "customer first, pioneering and innovative", and still achieved stable and notable results. Looking back on this year, every moment shines because of unremitting struggle.
At the intersection of the end of the year, we sincerely invite you to join us in focusing on the shining points of the year, and to look back together and cherish the bright moments that have illuminated our way forward in the past year.
.png "/uploads/image/2025/01/07/红白色商务风喜报微信公众号封面 (微信公众号封面).png")
Enabling Pharmaceutical R&D and Breakthrough Clinical Trials
In 2024, SDM continued to deepen its services and empower its partners to help many sponsors conduct groundbreaking clinical trials. With rich experience and deep industry accumulation, our professional team provides customized clinical development strategy, registration, clinical project management and operation, bioanalytical and other solutions to our clients, and has supported many of the country's first drug, vaccine, medical aesthetic, and medical device clinical projects in a variety of fields, including oncology, endocrinology, hepatology, hematology, ophthalmology, and so on. We operate efficiently to accelerate the clinical research process while ensuring trial quality and compliance to move pharmaceutical products to the next stage and benefit patients.
In 2024, SDM further broadened its service capabilities by successfully acquiring Amador Hangzhou and building and operating a brand new laboratory (Beijing Shouyan) in Beijing Daxing District. The Beijing Daxing lab focuses on vaccine clinical bioanalysis, small molecule drug testing and traditional Chinese medicine testing, while the Hangzhou Amador focuses on bioanalysis and biomarker research in cutting-edge areas such as large molecule drugs, XDC, CGT, and so on. The two labs, each with its own strengths in different fields, operate synergistically in the north and south, follow a unified management system that meets international quality standards, and provide more personalized and customized one-stop bioanalytical services for the industry.
In the middle of the year, SDM formally established the International Registration Division and set up a professional team to focus on providing multinational registration filing services for both domestic and foreign sponsors. This initiative further expands and deepens our global service capabilities, ensuring that our clients' registration filing processes in different regions are more efficient and compliant.
Strategic cooperation and resource sharing to help the industry win-win development
In 2024, SDM launched strategic cooperation with several industry leaders, covering quantitative pharmacology, hospitals, specialties, and globalization services and other dimensions. By sharing resources and complementing each other's strengths, both parties have accelerated their own development in technology. We believe that in-depth cooperation and experience exchange will promote the development of the industry more efficiently.
Digitalization powers operations and improves operational efficiency
In 2024, Stamm also took important steps forward in internal management and operations.Comprehensively promoting the digital transformation of internal operation and management not only ensures the security of data, but also greatly improves the work efficiency, providing customers with more accurate and efficient services.
In addition, SDM's official website (WWW.SDMCRO.COM) was newly launched, which comprehensively showcases our full-process one-stop clinical development services.Through this platform, global customers can access information more conveniently and further enhance their customer experience.
Shining at industry events
.jpg "/uploads/image/2025/03/05/未命名 (600 x 200 像素).jpg")
Time flies like a white horse, SDM has gone through 19 years and ushered in its 20th year.
Standing on the starting point of the new year, with higher goals and farther vision, we will continue to uphold the concept of "sincere collaboration, professional and effective", continue to plough into the Chinese market and expand our international vision. We will further promote innovation and breakthroughs in clinical research, broaden our business scope and strengthen international cooperation. We are committed to providing high-quality one-stop clinical development solutions for the global pharmaceutical industry, helping pharmaceutical R&D and marketing processes, and benefiting global human health.
In the future, SDM will continue to move forward to meet more challenges and opportunities.We look forward to working with you to create a more brilliant tomorrow.
New Year's Spring is the beginning of a new era. We wish you a happy New Year's Day!
KY-0301 is the world's first nano-dual-anti-ADC developed by Novatim based on its own innovative nano-dual-anti-ADC platform “TPEBEN”.
Beijing Shouyan Lab is certified by NGSP in the United States.
Provide diverse and better treatment options for patients worldwide.
At the intersection of the end of the year, we sincerely invite you to join us in focusing on the shining points of the year, and to look back together and cherish the bright moments that have illuminated our way forward in the past year.
On October 24-25 2024, Dr. Yuwen, CBO and SVP of SDM Bioservices, was invited to attend the 2024 International Biomedical Industry Innovation Beijing Forum co-sponsored by DIA and Beijing Advanced Medical Equipment Industry Innovation Alliance. The forum brings together representatives of global regulators, leading experts in biomedicine, industry leaders and academics to discuss the latest trends and industry innovations in global drug development.
AMWC China 2024 World Congress on Aesthetics and Anti-Aging was successfully carried out in Chengdu on October 18-20, 2024, with medical and aesthetic experts, scholars, and industry practitioners from all over the world participating and presenting their latest achievements.
On July 24, SDM Bioserices and Australia JP Medical Consulting Pty Ltd (hereinafter referred to as "JP Medical Consulting") announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of the two sides in the field of medicine in China and Australia, promote the internationalization of clinical trials and new drug research and development, and provide one-stop services for Chinese biopharmaceutical enterprises in Australian clinical trials.
August 1, China, Beijing, Liu Xueliang, deputy secretary of the District Party Committee and district governor, led a team to visit key enterprises of Daxing biomedical Industry Base to investigate the development and construction of pharmaceutical research and development service platform enterprises.
On the way to further explore and promote the professional development of medical clinical trials, SDM and Tonghua Dongbao jointly successfully held a nine-month "Diabetes Professional CRA Series course".
On July 11-12, 2024, MedDRA MSSO successfully held the fourth offline face-to-face training of 2024 at the Shenyang office of SDM. As the organizer of this event, SM gathered together with more than 40 experts from various fields such as CRO, pharmaceutical companies and partners, including medical coders, data management and statistics, drug safety/pharmacovigilance, medical writers and other modules.
On July 3, 2024, SDM Bioservices and Shanghai Ruiningkang Bio-Pharmaceutical Technology Development Co., LTD. (" Ruiningkang Bio ") reached a strategic cooperation to work together to help innovative drugs in the quantitative pharmacology, dose exploration level, and promote more innovative drugs with global competitiveness to the market.
On November 21, 2023, Beijing Kangle Guard Biotechnology Co., Ltd. is affiliated with Muhammadiyah University Malang, Indonesia (at) to start the "restructuring nine price 6/11/16/18/31/33/45/52/58) human papilloma virus (HPV) vaccine (e. coli) phase III clinical trials into the group of vaccination. As a CRO focused on vaccine clinical trials, Shanghai SDM undertook the phase III clinical study of the vaccine project in Indonesia, responsible for project management, data management, biostatistical analysis, pharmacovigilance and other important work of the project.
The laboratories operated by SDM in the North and South have their own specialties and technical advantages. Among them, Beijing Shouyan, with several P2 and P2+ laboratories and complete PCR testing facilities, is one of the few testing organizations in China focusing on bioanalysis of vaccines and traditional Chinese medicines; Hangzhou Amador focuses on XDC, macromolecules, and CGT, etc., and provides one-stop bioanalytical services for ADC drugs, which is a technological leader in the industry.
Meiji has advanced its oral paclitaxel softgel capsule, MJC-001, to clinical trial stage. With support from SDM Bioservices, Meiji received FDA clearance for its Investigational New Drug (IND) application, positioning it among the leading developers of oral paclitaxel formulations.
Listen to Dr. Liping Shen: Innovating Vaccine Bioanalysis for Change
KY-001 is an oral small-molecule inhibitor targeting the YAP/TAZ-TEAD interaction in the Hippo pathway with a proposed indication for advanced solid tumors driven by Hippo dysregulation.
Get in touch with SDM experts for your questions or comments and a member of our team will get back to you directly.
Let's Start a Conversation
